• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Jelmyto a “paradigm shift” in treating upper tract urothelial carcinoma

Video

“What's great about [Jelmyto] is you can avoid a pretty morbid operation in a typically unhealthy older population, and treat them with localized therapy,” says Jason M. Hafron, MD.

In a video interview conducted at the 2021 LUGPA annual meeting, Jason M. Hafron, MD, discusses his experience with mitomycin-containing reverse thermal gel (Jelmyto) in the treatment of low-grade upper tract urothelial cancer. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of urology at the William Beaumont School of Medicine, Oakland University; and the director of robotic surgery at Beaumont Hospital Royal Oak in Michigan.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.